These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 29477381

  • 1. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
    Gou W, Zhou X, Liu Z, Wang L, Shen J, Xu X, Li Z, Zhai X, Zuo D, Wu Y.
    Cancer Lett; 2018 May 28; 422():19-28. PubMed ID: 29477381
    [Abstract] [Full Text] [Related]

  • 2. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.
    Clin Cancer Res; 2015 Jan 01; 21(1):166-74. PubMed ID: 25351743
    [Abstract] [Full Text] [Related]

  • 3. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
    Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF.
    Clin Cancer Res; 2021 May 15; 27(10):2899-2909. PubMed ID: 33685866
    [Abstract] [Full Text] [Related]

  • 4. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
    Song A, Kim TM, Kim DW, Kim S, Keam B, Lee SH, Heo DS.
    Clin Cancer Res; 2015 May 15; 21(10):2379-87. PubMed ID: 25688157
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z, Shen L, Ding D, Huang J, Zhang J, Chen Z, Lu S.
    J Thorac Oncol; 2018 Jul 15; 13(7):987-995. PubMed ID: 29704675
    [Abstract] [Full Text] [Related]

  • 6. CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.
    Xu X, Li Y, Xu R, Meng Y, Li Z, Zuo D, Wu Y.
    FEBS J; 2024 Mar 15; 291(6):1199-1219. PubMed ID: 38148635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K.
    Cancer Sci; 2018 Oct 15; 109(10):3149-3158. PubMed ID: 30053332
    [Abstract] [Full Text] [Related]

  • 9. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
    Wu X, Wang Y, Wan S, Zhang J.
    J Biomol Struct Dyn; 2018 Sep 15; 36(12):3106-3113. PubMed ID: 28893136
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
    Xu H, Zhang Q, Liang L, Li J, Liu Z, Li W, Yang L, Yang G, Xu F, Ying J, Zhang S, Wang Y.
    Cancer Med; 2020 May 15; 9(10):3328-3336. PubMed ID: 32168429
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
    Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR.
    Proc Natl Acad Sci U S A; 2015 Mar 17; 112(11):3493-8. PubMed ID: 25733882
    [Abstract] [Full Text] [Related]

  • 20. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
    Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, Aisner DL, Doebele RC.
    J Thorac Oncol; 2016 Aug 17; 11(8):1273-1281. PubMed ID: 27068398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.